FORMULARY UPDATES ABUHB s Drug Formulary is at:
|
|
- Randolf Dickerson
- 5 years ago
- Views:
Transcription
1 Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: September 2015 Dear Gwent Prescriber In the first section of this prescribing newsletter there is a selection of the Formulary decisions made by ABUHB s Medicines & Therapeutics Committee during the course of its last three meetings (12 th March, 30 th April and 18 th June 2015): FORMULARY UPDATES ABUHB s Drug Formulary is at: BNF section LINACLOTIDE ( Constella ) for IBS ADDED as an option in the symptomatic treatment of moderate to severe irritable bowel syndrome (IBS) with constipation. AWMSG advice is that use of linaclotide should be restricted to adults who have not responded adequately to, or cannot tolerate antispasmodics and/or laxatives. The MTC agreed that the advice on linaclotide in NICE guidance on IBS (update to CG61, at: published in February 2015, should be adopted locally. This states that linaclotide may be considered for people with IBS only if: optimal or maximum tolerated doses of previous laxatives from different classes have not helped and they have had constipation for at least 12 months. NICE CG61 also advises to follow up people taking linaclotide after 3 months. Despite these restrictions it was agreed that linaclotide was appropriate for prescribing by all prescribers within Gwent (Green Traffic Light designation this is consistent with the previous Green classification of both prucalopride and lubiprostone). AWMSG Advice No 0314 on linaclotide in IBS can be found at: Full prescribing information on linaclotide is at: BNF section APIXABAN ( Eliquis ) for the treatment & secondary prevention of DVT and/or PE LICENSE EXTENSION APPROVED in accordance with the recommendation in NICE TA341. Consistent with the advice for dabigatran and rivaroxaban in their DVT/PE indications, apixaban has been designated Amber (specialist initiation only) in the Formulary. See table on Page 4 of this newsletter for further information on Traffic Light classification of oral anticoagulants. Full prescribing information on apixaban is at: RIVAROXABAN ( Xarelto ) in the acute management of ACS LICENSE EXTENSION APPROVED as an option (in combination with aspirin plus clopidogrel or aspirin alone) for preventing atherothrombotic events in people who have had an acute coronary syndrome with elevated cardiac biomarkers, in accordance with NICE TA335. Considering the setting for this use it was designated Amber (specialist initiation only) in the Formulary. See table on Page 4 of this newsletter for further information on Traffic Light classification of oral anticoagulants. Full prescribing information on rivaroxaban is at: Page 1 of 7
2 BNF section 2.12 COLESEVELAM (Cholestagel ) for primary hypercholesterolaemia ADDED as an option for adjunctive therapy (to diet) to provide an additive reduction in LDL C levels in primary hypercholesterolaemia, and with the following restrictions: 1. Used in adults with intolerance or contraindications to statins or ezetimibe i.e. in accordance with the recommendation in NICE CG71 on the management of familial hypercholesterolaemia (FH), at: The recommendation for children with FH, who are intolerant of statins, in CG71 is to consider offering bile acid sequestrants (as opposed to offer ), however the BNFc states that bile acid sequestrants are not well tolerated and compliance with treatment was poor, therefore they were rarely used in children. 2. For specialist initiation only (i.e. designated Amber). This concurred with the recommendation on referral to a specialist in CG Colesevelam should only be used in those individuals who have tried colestyramine (Questran /Questran Light ) and who have either developed gastrointestinal adverse effects and/or tolerability problems which are significant enough to be detrimental to their continuing adherence colesevelam has a significantly increased acquisition cost and a narrower administration window (in patients taking other medication) compared to colestyramine. Full prescribing information on colesevelam is at: BNF section Umeclidinium/vilanterol ( ANORO Ellipta ) 55micrograms/22micrograms inhaler for COPD ADDED in accordance with AWMSG Advice No Anoro Ellipta is recommended as an option for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. This fixed dose combination is considered suitable for prescribing by all prescribers in Gwent (i.e. designated Green in the Traffic Light classification). AWMSG Advice No 0215 on Anoro in COPD can be found at: Full prescribing information on Anoro is at: BNF section LURASIDONE ( Latuda ) tablets for schizophrenia ADDED in accordance with AWMSG Advice No Lurasidone is recommended as an option for the treatment of schizophrenia in adults. The MTC agreed that non specialist repeat prescribing, without the need for a shared care protocol, was appropriate following specialist initiation (i.e. Amber in the local Traffic Light system). Local guidance on lurasidone (2 pages) is available on the Mental Health Prescribing Guidelines and Resources page of MTC s website: AWMSG Advice No 0215 on lurasidone can be found at: Full prescribing information on lurasidone is at: Page 2 of 7
3 BNF section RIFAXIMIN 550mg tablets ( Targaxan ) for hepatic encephalopathy ADDED in accordance with NICE TA337. This recommends rifaximin as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in adults. The MTC agreed that non specialist repeat prescribing of the 550mg tablets was appropriate following specialist initiation (i.e. Amber in the local Traffic Light system). This is consistent with the previous Amber designation of rifaximin 200mg ( Xifaxanta) for the treatment of travellers diarrhoea (AWMSG Advice No. 1212). Full prescribing information on rifaximin 550mg is at: BNF section EMPAGLIFLOZIN ( Jardiance ) for type 2 diabetes ADDED in accordance with NICE TA341. This recommends empagliflozin as an option (in combination with metformin, metformin plus a sulfonylurea, metformin plus a thiazolidinedione or in combination with insulin) for treating type 2 diabetes. Consistent with the local advice for dapagliflozin and canagliflozin, empagliflozin is considered suitable for prescribing by all prescribers in Gwent (i.e. designated Green in the traffic light classification). A NICE multiple technology appraisal of all 3 SGLT2 inhibitors (flozins) as monotherapy in type 2 diabetes is in development, with publication due in May Full prescribing information on empagliflozin is at: BNF section 11.6 BIMATOPROST 0.03% (Lumigan ) SINGLE USE eye drops for the reduction of intraocular pressure ADDED in response to the announcement by Allergan that bimatoprost (Lumigan ) 0.03% eye drops in the 3mL multidose bottle would cease to be available from 30 April Local advice on options for the management of patients established on bimatoprost 0.03% multidose drops was developed, in consultation with ABUHB Ophthalmology, and ed to GP practices (and opticians) in May. The guidance advised use of bimatoprost 0.03% SINGL USE (and preservative free [p/f]) eye drops only in cases where Monopost (p/f latanoprost) AND p/f tafluprost (Saflutan ) were not tolerated (or failed to deliver a sufficient reduction in IOP). Full prescribing information on bimatoprost 0.03% eye drops in single dose container is at: Local advice on options for the management of patients established on bimatoprost 0.03% multidose drops (1 page) is available at: DiscontinuationAdvice14May2015.pdf OTHER PRESCRIBING NEWS SHARED CARE PROTOCOLS (SCPs) Prescribers should note the following changes to Gwent Protocols: 1. SUB CUT METHOTREXATE (Metoject ) UPDATED SCP. Now extended to cover the prescribing and monitoring of Metoject in psoriasis. 2. MYCOPHENOLATE MOFETIL (MMF) 500mg tablets in connective tissue diseases NEW SCP covering the off label use as a disease modifying drug in connective tissue disease responding to immunosuppressive therapy when other standard treatments (e.g. azathioprine) have failed or are not tolerated. Connective tissue disease covers; rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis and inflammatory myopathy such as dermatomyositis and polymyositis. MMF is also used in scleroderma, vasculitis and Behçet s disease. Page 3 of 7
4 Primary Care prescribers should note: The monthly monitoring schedule set out in the SCP is now covered by the DMARD monitoring Local Enhanced Service and can be claimed for. The transfer arrangements to GP practice prescribing/monitoring in this new SCP require the rheumatology specialist to fax the Shared Care Agreement Form (included at the end of the SCP document) to the GP only once they have reviewed the result of the 4 th blood test. The initial monitoring at 1, 2, 3 and 4 weeks post initiation is the responsibility of Rheumatology and they will provide the patient with FOUR blood sample request forms for this and six weeks of medication. All other DMARD SCPs will now be updated in line with this agreed arrangement. 3. AChE Inhibitors EXTENDED SCP. Use of acetylcholinesterase inhibitors (donepezil [e.g. Aricept ], galantamine [e.g. Reminyl ] and rivastigmine [e.g. Exelon ]) in Parkinson s disease dementia is now also covered by the SCP. All the Gwent Shared Care Protocols and the Incident Report Form can be found at: TRAFFIC LIGHT CHANGES 1. TOBI Podhaler and Colobreathe dry powder inhalers Now Red (specialist only prescribing) These antibiotic inhalations, both used in the management of chronic pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF), are not recommended for prescribing in Primary Care. This clarification follows advice received from the Lead Respiratory Pharmacist at Llandough Hospital. It is understood that the Patient Access Scheme discount (which was a condition of NICE TA276, when it recommended both the Podhaler and Colobreathe ) is only available to Secondary/Tertiary care and to homecare providers. Note that TOBI and Bramitob nebuliser solutions for CF remain designated Amber with Shared Care. 2. RIVAROXABAN for stroke prevention in non valvular AF Now Green (appropriate for initiation by non specialist prescribers in Gwent Primary Care). This decision was communicated to GP practices at the beginning of June: The table below summarises the current Traffic Light Status for the main uses of oral anticoagulants in Gwent: Drug Indication Traffic Light Status* Warfarin Preventing VTE in rheumatic heart disease and AF GREEN Warfarin Prophylaxis after insertion of prosthetic heart valves AMBER Warfarin Treating and preventing DVT/PE AMBER Rivaroxaban ( Xarelto) Preventing stroke and systemic embolism in non valvular AF GREEN Apixaban ( Eliquis) Preventing stroke and systemic embolism in non valvular AF AMBER Dabigatran (Pradaxa) Preventing stroke and systemic embolism in non valvular AF AMBER Apixaban ( Eliquis) Dabigatran (Pradaxa) Rivaroxaban ( Xarelto) Apixaban ( Eliquis) Dabigatran (Pradaxa) Rivaroxaban ( Xarelto) Treating and preventing DVT/PE Preventing VTE in adult patients undergoing elective hip or knee replacement surgery AMBER RED Rivaroxaban ( Xarelto) Preventing adverse outcomes after acute management of ACS AMBER * Definitions of ABUHB s Traffic Light drug classifications can be found at The Traffic Light classifications of all medicines included in the ABUHB Formulary can be found at: Page 4 of 7
5 GOUT newly developed local treatment algorithm This local treatment pathway was ed to GP practices in early July and is available on the MTC s website at: ABUHBguidelinesFINAL%5BJune2015%5D.pdf Two key prescribing points to note are: 1. The importance, in the long term management of gout, of treating to target serum uric acid (sua) levels of < 300µmol/L, for which doses of allopurniol above 300mg daily may be required. 2. febuxostat (Adenuric ) is now designated Green in ABUHB s Traffic Light classification. The MTC agreed that it is suitable for GP initiation provided that it is used where recommended in the algorithm. METFORMIN use in renal disease Following discussion of the views in a BMJ editorial ( on using metformin in the presence of renal disease the MTC agreed to highlight the following points to prescribers: Guidelines from NICE on type 2 diabetes (CG ) suggest that metformin dose should be reviewed at an egfr of 45 and stopped at an egfr of 30. The draft update of this guideline (due October 2015) states: review the dose of metformin if the egfr is below 45 ml/minute/1.73m 2 : Stop metformin if the egfr is below 30 ml/minute/1.73m 2. Prescribe metformin with caution for those at risk of a sudden deterioration in kidney function and those at risk of egfr falling below 45 ml/minute/1.73m 2. ABUHB s 2013 document Acute Kidney Injury (AKI): Advice to Primary Care (1page) is available at: The NHS campaign THINK KIDNEYS issued an Interim Position Statement in July 2015 on Sick day rules in patients at risk of AKI. This states that a systematic review of the published evidence on this topic is under way and that the position statement is provided as a temporary measure until that review is completed. In terms of medicines management, advice from the THINK KIDNEYS Programme Board is that it is reasonable for clinicians to provide sick day rules guidance on temporary cessation of medicines to patients deemed at high risk of AKI based on an individual risk assessment. However, they consider that investment in a systematic approach to increase uptake of sick day rules by patients should only be undertaken in the context of a formal evaluation. content/uploads/2015/07/think Kidneys Sick Day Rules pdf Prescribing Dilemmas: A Guide for Prescribers guidance on prescribing situations not covered by NHS Wales This all Wales guidance (first produced in 2011) has recently been reviewed and updated. It provides useful advice on a range of prescribing situations including private care and private prescriptions, travel, foodstuffs, infertility treatment, common ailments, complementary medicines and alternative therapies, erectile dysfunction, prescribing for self and family, visitors from overseas, unlicensed medicines, and prescribing outside national guidance. The updated document can be accessed on the link below: %20A%20Guide%20for%20Prescribers.pdf Page 5 of 7
6 Local Antibiotic Guidelines Updated The local antibiotic guidelines were updated in July to include new indications and revised recommendations. The changes are as follows: NEW guidance: Sepsis (non shock) unknown origin (as part of Sepsis Six) to be used for patients without severe sepsis Herpes simplex encephalitis Leg ulcers (Secondary Care) PEG/PEJ insertion prophylaxis Endoscopic ultrasound aspiration prophylaxis Revised guidance: Threadworm in age <6/12 (in Primary Care section) Penicillin allergy Sensitivity rates Gwent Primary Care Bronchiectasis (H. influenzae) ERCP prophylaxis Breast surgery prophylaxis C section prophylaxis Teicoplanin levels C. diff intracolonic vancomycin The guidelines can be accessed online at: guidelines.com/view/abuhb/abx, via the link on the CWS homepage or via the ABUHB applications page, and using the Apple & Android App (search RxGuidelines if using the App, ensure you download the new guidelines when prompted). Prescribing for Care Home residents The MTC strongly endorses two requests from the ABHB Pharmacist with a role dedicated to managing medicines in Care Homes. These requests (to all prescribers, and where it is know that the individual is a Care Home resident) are that you please consider: 1. Reducing the use of take/use as directed on prescriptions (e.g. adding durations for topical steroids and specifying which eye/eyes require the drops) whenever possible. NICE s Social Care Guidance on Managing medicines in care homes (SC1 at: states: GP practices should ensure that there is a clear written process for prescribing and issuing prescriptions for their patients who live in care homes. The process should cover: recording clear instructions on how a medicine should be used, including how long the resident is expected to need the medicine and, if important, how long the medicine will take to work and what it has been prescribed for (use of the term 'as directed' should be avoided). 2. Adding clinical indications to when required medicines (e.g. haloperidol for hiccups or psychosis?). The 2013 GMC guidance on prescribing (at: uk.org/guidance/ethical_guidance/14317.asp) advises you should consider including clinical indications* on your prescriptions. * See clinicalindications.com Chronic Cough This MTC endorsed local guidance on the investigation, management and referral of this common condition was ed to GP practices at the beginning of July. It has been developed by ABUHB s Department of Respiratory Medicine and it included (on page 3) a diagnostic and therapeutic algorithm covering the 3 commonest causes of chronic cough: 1. Gastro oesophageal reflux related cough [37%] 2. Asthma and asthma like syndromes [33%] 3. Rhinitis, sinusitis, post nasal drip [10%] The algorithm also includes detail on ACE inhibitor associated cough. The 6 page document can be accessed via the link below: Page 6 of 7
7 PATIENT INFORMATION on medication for mental health REMINDER In the MTC s last enewsletter this source of simple and accurate patient information on medication for mental health was highlighted (in the item on valproate medicines in pregnancy). The link to this website is: The website is structured into two main strands: 1. Medicines at least 30 questions and answers on over 150 medicines used in mental health Under most medicines there is a link to "download a handy PILL". 2. Conditions at least 14 questions and answers on 21 or so conditions The link to the printable leaflets webpage (medicines listed in alphabetical order) is: DuoResp Spiromax and Symbicort Turbohaler reminder to prescribe as brands Further to the item in the MTC s last enewsletter on addition of the DuoResp Spiromax breathactuated Dry Powder Inhaler device (for COPD and asthma) to ABUHB s Formulary, advice was issued to GP practices at the end of July to prescribe DuoResp and Symbicort devices by BRAND (rather than as generic budesonide/formoterol strengths). This should avoid confusion as, although the two doses of DuoResp are bioequivalent to two of the three Symbicort Turbohaler devices, the doses are differently stated: DuoResp dose is the delivered dose (the dose that leaves the mouthpiece) Symbicort dose is the metered dose (the dose held within the chamber after priming). Feedback on any item in this enewsletter is welcome. Suggested agenda items for the MTC are also welcome. Trevor Batt Pharmacist & Professional Secretary to: Aneurin Bevan HB Medicines & Therapeutics Committee Aneurin Bevan Health Board Based at Victoria House, Corporation Rd, Newport NP19 0BH trevor.batt@wales.nhs.uk Tel: (DIRECT LINE) Web: Page 7 of 7
FORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber At its last
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (9 th September and 21 st October 2010) the Gwent Partnership Medicines & Therapeutics Committee (GPMTC) made the following decisions in relation to the Aneurin
More informationAneurin Bevan Health Board Medicines & Therapeutics Committee. enewsletter
Aneurin Bevan Health Board Medicines & Therapeutics Committee August 2013 enewsletter Dear Gwent Prescriber At its last two meetings (23 rd May and 11 th July) ABHB s Medicines & Therapeutics Committee
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
ANEURIN BEVAN UNIVERSITY HEALTH BOARD MEDICINES & THERAPEUTICS COMMITTEE PRESCRIBING enewsletter 28 September 2016 ARCHIVE at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationINTRODUCTION Indication and Licensing
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: Apixaban (Eliquis ) Transfer of Care document Indication: Treatment of acute venous thromboembolism
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationDRUG: Introduction. `Shared Care Guidelines. They can also be used long term for chronic pulmonary Pseudomonas aeruginosa infection.
`Shared Care Guidelines DRUG: Introduction Inhaled antibiotics (Adults and Paediatrics) in Cystic Fibrosis. EXISTING ESTABLISHED PATIENTS ONLY Colistimethate (Colomycin, Promixin ) Tobramycin (Tobi Bramitob
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee July 2014 PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationRivaroxaban film coated tablets are available in 2 strengths for this indication: 15mg and 20mg.
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Rivaroxaban is a non-vitamin K antagonist
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationEdoxaban Switch Programme - Frequently Asked Questions
Edoxaban Switch Programme - Frequently Asked Questions What should I tell patients? NHS Tayside is reviewing all patients currently receiving a Direct Oral Anticoagulant (DOAC) for stroke prevention in
More information2 Summary of NICE TA 249: Atrial fibrillation - Dabigatran Etexilate
Service Notification in response to DHSSPS endorsed NICE Technology Appraisals NICE TA 249: Atrial fibrillation - Dabigatran Etexilate 1 Name of Commissioning Team Long Term Conditions Commissioning Team
More informationEFFECTIVE SHARED CARE AGREEMENT (ESCA)
WORKING IN PARTNERSHIP WITH EFFECTIVE SHARED CARE AGREEMENT (ESCA) DRUG NAME: ACETYLCHOLINESTERASE-INHIBITORS AND MEMANTINE INDICATION/S COVERED: Dementia in Alzheimers Disease Coastal West Sussex Traffic
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism INDICATION Edoxaban is a non-vitamin K antagonist oral
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationPrescribing Framework for Galantamine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Galantamine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Anticoagulants Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Anticoagulant - Bevyxxa (betrixaban), Eliquis (apixaban), Pradaxa (dabigatran),
More informationA NEBULISERS AND NEBULISED MEDICATION. Generic Guide for the use of nebulisers and nebulised medication
A NEBULISERS AND NEBULISED MEDICATION Generic Guide for the use of nebulisers and nebulised medication Aim The aim of this guide is to provide a template for those who wish to develop their own nebuliser
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationPrimary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information RIVAROXABAN (XARELTO ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Rivaroxaban is a non-vitamin K antagonist oral anticoagulant
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationProducts available Methotrexate tablets 2.5mg ONLY (Methotrexate tablets 10mg are NOT recommended as per NPSA guidance 5 ).
Methotrexate Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti
More informationCosting Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180)
Putting NICE guidance into practice Costing Report: atrial fibrillation Implementing the NICE guideline on atrial fibrillation (CG180) Published: June 2014 This costing report accompanies the clinical
More informationSummary of Main Points from the Meeting held on Monday 12 th December 2016
Summary of Main Points from the Meeting held on Monday 12 th December 2016 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the November 2016 Medicines Group meeting were
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More informationDRUG NAME: EDOXABAN (LIXIANA ) Transfer of Care document Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
City and Hackney Clinical Commissioning Group Homerton University Hospital Foundation Trust DRUG NAME: EDOXABAN (LIXIANA ) Treatment of acute venous thromboembolism and prevention of recurrent venous thromboembolism
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last three meetings (12 th January, 1 st March and 19 th April 2012) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationEffective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine
Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationAppendix C Factors to consider when choosing between anticoagulant options and FAQs
Appendix C Factors to consider when choosing between anticoagulant options and FAQs Choice of anticoagulant for non-valvular* atrial fibrillation: Clinical decision aid Patients should already be screened
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 12 No 10, November 2018 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationNHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation
1 NHS Lanarkshire Guidance on Anticoagulant treatment for patients with non-valvular atrial fibrillation Atrial fibrillation (AF) affects about 1.2% of the population in the United Kingdom and accounts
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationpatient group direction
ASPIRIN v01 1/8 ASPIRIN PGD Details Version 1.0 Legal category P Staff grades Approved by Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationSOMERSET PRESCRIBING FORUM
SOMERSET PRESCRIBING FORUM Minutes of the meeting held at Wynford House, Yeovil, on Wednesday 14 November 2012 Present Position Initials Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS Foundation
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE July 5, 2016 SUBJECT EFFECTIVE DATE July 11, 2016 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Anticoagulants - Pharmacy Services Leesa M. Allen, Deputy Secretary
More informationDuration of treatment All DMARDs are long term treatments. Clinical benefit may take up to 6 months. 1
Leflunomide Traffic light classification- Amber 1 Information sheet for Primary Care Prescribers Part of the Shared Care Protocol: Management of Rheumatological Conditions with Disease-Modifying Anti Rheumatic
More informationAppendix D Clinical specialist statement template
Appendix D Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis Thank you for agreeing to give us a statement on your organisation
More informationVolume 7; Number 10 June 2013
Volume 7; Number 10 June 2013 What s new this month? The Viagra patent is due to expire in June 2013 followed by the launch of lower cost generic sildenafil tablets 25mg, 50mg and 100mg. Prescribers should
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationNEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION:
DUE CARE PROGRAM NEWSLETTER WINTER 2014 Summer 2015 Lisa Sather, RPh DUR Coordinator Mountain-Pacific Quality Health 3404 Cooney Drive Helena, MT 59602 406-457-5818 The DUE CARE PROGRAM, administered by
More informationInterface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE
Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable
More informationFactsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction
North Central London Joint Formulary Committee Factsheet Sacubitril valsartan (Entresto ) for chronic heart failure with reduced ejection fraction Start date: July 2016 Review date: July 2019 Document
More informationDeep Vein Thrombosis
Deep Vein Thrombosis from NHS (UK) guidelines Introduction Deep vein thrombosis (DVT) is a blood clot in one of the deep veins in the body. Blood clots that develop in a vein are also known as venous thrombosis.
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (13 th October and 24 th November 2011) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to the ABHB Joint
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More informationClinical Policy: Dabigatran (Pradaxa) Reference Number: CP.PMN.49 Effective Date: Last Review Date: 05.18
Clinical Policy: (Pradaxa) Reference Number: CP.PMN.49 Effective Date: 05.01.12 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationFactsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C)
North Central London Joint Formulary Committee Factsheet LINACLOTIDE (Constella ) Irritable Bowel Syndrome constipation predominant (IBS-C) Start date: September 2018 Review date: September 2021 Document
More informationSHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation in Adults
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: Mycophenolate mofetil or mycophenolic acid for Maintenance of Immunosuppression after Kidney Transplantation
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes
National Institute for Health and Care Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Empagliflozin combination therapy for treating type 2 diabetes Response to consultee and commentator
More informationPrimary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation
Primary Care Prescriber Information EDOXABAN (LIXIANA ) Prevention of stroke and embolism for nonvalvular atrial fibrillation INDICATION Edoxaban is a non-vitamin K antagonist oral anticoagulant (NOAC)
More informationNEBULISERS AND NEBULISED MEDICATION. A Guide for the use of nebulisers and nebulised medication in the community setting
NEBULISERS AND NEBULISED MEDICATION A Guide for the use of nebulisers and nebulised medication in the community setting Aim This guide has been developed from the generic guidance circulated in April 2014.
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationWITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER
WITBANK COALFIELDS MEDICAL AID SCHEME (WCMAS) CHRONIC MEDICINE PROGRAMME GENERAL INFORMATION LETTER The Prescribed Minimum Benefit Chronic Disease List In terms of the Medical Scheme Act Regulations that
More informationSAFE study A-fib ED Anticoagulation Package
SAFE study A-fib ED Anticoagulation Package In this package you will find documents to help you make decision making easy for the Anticoagulation of New AFib patients being discharged from the ED: 1. Anticoagulation
More informationPrescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil for Immunosuppression in ADULTs Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker)
More informationNational Institute for Health and Care Excellence. Type 2 diabetes. Stakeholder Comments Draft Guideline
National Institute for Health and Care Excellence Type 2 diabetes Stakeholder Comments Draft Guideline NOTE: NICE is unable to accept comments from non-registered organisations or individuals. If you wish
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationHydroxychloroquine (Adults)
Shared Care Guideline DRUG: Introduction: Contraindications & Warnings: Hydroxychloroquine (Adults) Indication: Rheumatoid arthritis and inflammatory osteoarthritis, discoid and systemic lupus erythematosus,
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationNOAC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions
AC Prescribing in Patients with Non-Valvular Atrial Fibrillation: Frequently Asked Questions FAQ document jointly prepared by NHSGGC Haematology Service & Medicines Infmation On behalf of the Heart MCN
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationLiving with a New Oral Anticoagulant (NOAC)
Living with a New Oral Anticoagulant (NOAC) dabigatran (Pradaxa ) rivaroxaban (Xarelto ) apixaban (Eliquis ) Information for patients Produced and made available by the Western Australian Medication Safety
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationNHS Circular: PCA(M)(2011)4 abcdefghijklmnopqrstu TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH SEVERE DISTRESS. Summary
Directorate for Health and Social Care Integration Primary Care NHS Circular: abcdefghijklmnopqrstu Dear Colleague LIST OF DRUGS SUBJECT TO PRESCRIBING TREATMENT OF ERECTILE DYSFUNCTION: PATIENTS WITH
More informationPrescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant
Hull & East Riding Prescribing Committee Prescribing Framework for Mycophenolate Mofetil or Mycophenolic Acid (Myfortic ) Post Solid Organ Transplant Patient s Name:.. NHS Number: Patient s Address:...
More informationBlood-thinning medication after stroke
Stroke Helpline: 0303 3033 100 Website: stroke.org.uk Blood-thinning medication after stroke Blood-thinning medicines are drugs that help to prevent clots forming in your blood. They are often prescribed
More informationAtrial fibrillation and anticoagulation therapy
Atrial fibrillation and anticoagulation therapy This leaflet offers more information about atrial fibrillation for patients who have been advised that they need anticoagulation therapy. If you have any
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationLipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)
Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Policy Statement: October 2010 This policy defines the decision made by NHS Wirral following an evidence review
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationDelirium. Quick reference guide. Issue date: July Diagnosis, prevention and management
Issue date: July 2010 Delirium Diagnosis, prevention and management Developed by the National Clinical Guideline Centre for Acute and Chronic Conditions About this booklet This is a quick reference guide
More informationPRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA
PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationVenous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital
Please Note: This policy is currently under review and is still fit for purpose. Venous Thromboembolism (VTE) Prevention and Treatment of VTE in Patients Admitted to Hospital This procedural document supersedes
More informationEdoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF
Edoxaban for the treatment and prevention of venous thromboembolism (DVT or PE) or stroke prevention in non-valvular AF Traffic light classification- Amber 2 specialist initiation / recommendation Information
More informationI. UNIFORM FORMULARY REVIEW PROCESS
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code 1074g, as implemented
More information